Activity Overview
Welcome to this OncoByte Personalized Learning Pathway!
Each OncoByte video consists of a 5-minute presentation delivered by our expert faculty on practice-ready updates in triple-negative breast cancer (TNBC) or a 10-minute panel discussion where our expert faculty will help you synthesize the latest information and data about TROP2-targeted ADCs to help guide your incorporation of these novel treatments into everyday practice.
For each module, select at least 3 videos to build a custom microlearning program focused only on your interests.
Target Audience
This educational program is primarily directed toward medical oncologists, surgical oncologists, advanced practice providers, nurses, and pharmacists involved in the management of patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess current standards of care and unmet needs for treating early-stage TNBC
- Describe the emerging role of ADCs in early-stage TNBC and potential practice implications of ongoing clinical trials
- Recognize key drivers of disparities in treatment outcomes, including access to biomarker testing, novel therapies, and clinical trials
- Enhance patient communication around treatment options, including treatment expectations, toxicity management, and shared decision-making
Nour Abuhadra, MD
Assistant Professor
Co-Director, Rare Breast Cancer Program, Department of Medicine
Co–Section Head, Triple Negative Breast Cancer Clinical Research Program, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Nour Abuhadra, MD, has no relevant financial relationships with ineligible companies.
Antonio Giordano, MD, PhD
Assistant Professor, Harvard Medical School
Clinical Director, Center for Cancer Therapeutic Innovation (Early Drug Development)
Medical Director, Breast Cancer Pathway
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Araris, AstraZeneca, Axis, Curio, DAVA, Eli Lilly, Guardant Health, MDEducation, Novartis, Pfizer, Totus Medicine; Grant/Research Funding: Cardiff Oncology
Aditya Bardia, MD, MPH, FASCO
Professor of Medicine, Geffen School of Medicine
University of California, Los Angeles
Program Director, Breast Medical Oncology
Assistant Chief of Translational Research, Division of Hematology-Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, CA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Alyssum, AstraZeneca/Daiichi, BMS, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Vyome; Grant/Research Funding: AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, OnKure, Pfizer
Kathryn E. Post, PhD, ANP-BC
Advanced Practice Provider Scholar
MassGeneral Brigham Cancer Institute
Assistant Professor
Harvard Medical School
Boston, MA
Disclosures: Kathryn E. Post, PhD, ANP-BC, has no relevant financial relationships with ineligible companies.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This
accredited continuing education activity was planned in accordance with the
ACCME Standards for Integrity and Independence to ensure balance, objectivity,
independence, and scientific rigor. Faculty were instructed to use generic
names when possible and to base recommendations on the best available evidence.
Proprietary product names may be referenced in clinical discussion for
educational purposes only and do not imply endorsement.
This activity
may include discussion of investigational, unapproved, or off‑label uses of drugs or devices.
Learners are advised to consult prescribing information for products discussed.
Content is provided for educational purposes only and is not a substitute for
the independent clinical judgment of a health care professional. Learners are
encouraged to critically evaluate the information presented and apply their own
clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.
